Multiple sclerosis and the ophthalmologist

Comprehensive Ophthalmology Update

Volumn 8, Issue 1, 2007, Pages 39-49

  Mowry, Ellen M ^a   Balcer, Laura J ^a   Galetta, Steven L ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b 3 East Gates Building ^*  (United States)

Author keywords

Acute demyelinating optic neuritis (optic neuritis); Low contrast letter acuity; Magnetic resonance imaging (MRI); Multiple sclerosis (MS); Optical coherence tomography (OCT)

Indexed keywords

BETA1A INTERFERON; CORTICOSTEROID; INTERFERON BETA SERINE; METHYLPREDNISOLONE; PLACEBO; PREDNISONE;

ANEMIA; CHILL; CLINICAL TRIAL; DEPRESSION; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG TOLERABILITY; EVOKED VISUAL RESPONSE; EYE MOVEMENT DISORDER; FEVER; FLU LIKE SYNDROME; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INJECTION SITE INFLAMMATION; INTERNUCLEAR OPHTHALMOPLEGIA; LIVER DYSFUNCTION; MOOD CHANGE; MULTIPLE SCLEROSIS; MYALGIA; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIC NEURITIS; OPTICAL COHERENCE TOMOGRAPHY; PATIENT CARE; PROGNOSIS; REVIEW; RISK FACTOR; SIDE EFFECT; SLEEP DISORDER; STOMACH DISCOMFORT; TREATMENT CONTRAINDICATION; VISION; VISUAL ACUITY; VISUAL FIELD DEFECT; WEIGHT GAIN;

DIAGNOSIS, DIFFERENTIAL; GLUCOCORTICOIDS; HUMANS; MAGNETIC RESONANCE IMAGING; MULTIPLE SCLEROSIS; OPTIC NEURITIS; PROGNOSIS; TOMOGRAPHY, OPTICAL COHERENCE; VISUAL ACUITY;

EID: 34047240841     PISSN: 15277313     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (84)

1. Noseworthy JH, Lucchinetti C, Rodriguez M, et al: Multiple sclerosis. N Engl J Med 343: 938-52, 2000
2. Trapp BD, Peterson J, Ransohoff RM, et al: Axonal transection in the lesions of multiple sclerosis. N Engl J Med 338: 278-85, 1998
3. Ferguson B, Matyszak MK, Esiri MM, et al: Axonal damage in acute multiple sclerosis lesions. Brain 120 (Pt 3): 393-9, 1997
4. Lucchinetti C, Brück W, Parisi J, et al: A quantitative analysis of oligodendrocytes in multiple sclerosis lesions. A study of 113 cases. Brain 122 (Pt 12): 2279-95, 1999
5. Balcer LJ: Clinical practice. Optic neuritis. N Engl J Med 354: 1273-80, 2006
6. Armstrong RA: Multiple sclerosis and the eye. Ophthalmic Physiol Opt 19 Suppl 2: S32-42, 1999
7. Visudhiphan P, Chiemchanya S, Santadusit S: Optic neuritis in children: recurrence and subsequent development of multiple sclerosis. Pediatr Neurol 13: 293-5, 1995
8. Wilejto M, Shroff M, Buncic JR, et al: The clinical features, MRI findings, and outcome of optic neuritis in children. Neurology 67: 258-62, 2006
9. Steinlin MI, Blaser SI, MacGregor DL, et al: Eye problems in children with multiple sclerosis. Pediatr Neurol 12: 207-12, 1995
10. Keltner JL, Johnson CA, Spurr JO, et al: Baseline visual field profile of optic neuritis. The experience of the optic neuritis treatment trial. Optic Neuritis Study Group. Arch Ophthalmol 111: 231-4, 1993
11. Balcer LJ, Baier ML, Cohen JA, et al: Contrast letter acuity as a visual component for the Multiple Sclerosis Functional Composite. Neurology 61: 1367-73, 2003
12. Balcer LJ, Baier ML, Pelak VS, et al: New low-contrast vision charts: reliability and test characteristics in patients with multiple sclerosis. Mult Scler 6: 163-71, 2000
13. Baier ML, Cutter GR, Rudick RA, et al: Low-contrast letter acuity testing captures visual dysfunction in patients with multiple sclerosis. Neurology 64: 992-5, 2005
14. Sisto D, Trojano M, Vetrugno M, et al: Subclinical visual involvement in multiple sclerosis: a study by MRI, VEPs, frequency-doubling perimetry, standard perimetry, and contrast sensitivity. Invest Ophthalmol Vis Sci 46: 1264-8, 2005
15. Andersson T, Sidén A: An analysis of VEP components in optic neuritis. Electromyogr Clin Neurophysiol 35: 77-85, 1995
16. Miller DH, Newton MR, van der Poel JC, et al: Magnetic resonance imaging of the optic nerve in optic neuritis. Neurology 38: 175-9, 1988
17. Frederiksen JL, Petrera J: Serial visual evoked potentials in 90 untreated patients with acute optic neuritis. Surv Ophthalmol 44 Suppl 1: S54-62, 1999
18. Gilmore RL: Sensory evoked potentials in clinical practice. Semin Neurol 10: 185-95, 1990
19. Filippini G, Comi GC, Cosi V, et al: Sensitivities and predictive values of paraclinical tests for diagnosing multiple sclerosis. J Neurol 241: 132-7, 1994
20. Kallmann BA, Fackelmann S, Toyka KV, et al: Early abnormalities of evoked potentials and future disability in patients with multiple sclerosis. Mult Scler 12: 58-65, 2006
21. Hickman SJ, Toosy AT, Miszkiel KA, et al: Visual recovery following acute optic neuritis - a clinical, electrophysiological and magnetic resonance imaging study. J Neurol 251: 996-1005, 2004
22. Diem R, Tschirne A, Bähr M: Decreased amplitudes in multiple sclerosis patients with normal visual acuity: a VEP study. J Clin Neurosci 10: 67-70, 2003
23. Weinstock-Guttman B, Baier M, Stockton R, et al: Pattern reversal visual evoked potentials as a measure of visual pathway pathology in multiple sclerosis. Mult Scler 9: 529-34, 2003
24. Fraser CL, Klistorner A, Graham SL, et al: Multifocal visual evoked potential analysis of inflammatory or demyelinating optic neuritis. Ophthalmology 113: 323.e1-323.e2, 2006
25. Fraser C, Klistorner A, Graham S, et al: Multifocal visual evoked potential latency analysis: predicting progression to multiple sclerosis. Arch Neurol 63: 847-50, 2006
26. Rocca MA, Hickman SJ, Bö L, et al: Imaging the optic nerve in multiple sclerosis. Mult Scler 11: 537-41, 2005
27. Jackson A, Sheppard S, Laitt RD, et al: Optic neuritis: MR imaging with combined fat- and water-suppression techniques. Radiology 206: 57-63, 1998
28. Hickman SJ, Miszktel KA, Plant GT, et al: The optic nerve sheath on MRI in acute optic neuritis. Neuroradiology 47: 51-5, 2005
29. Kupersmith MJ, Alban T, Zeiffer B, et al: Contrast-enhanced MRI in acute optic neuritis: relationship to visual performance. Brain 125: 812-22, 2002
30. Hickman SJ, Toosy AT, Jones SJ, et al: A serial MRI study following optic nerve mean area in acute optic neuritis. Brain 127: 2498-505, 2004
31. Hickman SJ, Brex PA, Brierley CM, et al: Detection of optic nerve atrophy following a single episode of unilateral optic neuritis by MRI using a fat-saturated short-echo fast FLAIR sequence. Neuroradiology 43: 123-8, 2001
32. Inglese M, Ghezzi A, Bianchi S, et al: Irreversible disability and tissue loss in multiple sclerosis: a conventional and magnetization transfer magnetic resonance imaging study of the optic nerves. Arch Neurol 59: 250-5, 2002
33. Hickman SJ, Brierley CM, Brex PA, et al: Continuing optic nerve atrophy following optic neuritis: a serial MRI study. Mult Scler 8: 339-42, 2002
34. Trip SA, Schlottmann PG, Jones SJ, et al: Retinal nerve fiber layer axonal loss and visual dysfunction in optic neuritis. Ann Neurol 58: 383-91, 2005
35. Fisher JB, Jacobs DA, Markowitz CE, et al: Relation of visual function to retinal nerve fiber layer thickness in multiple sclerosis. Ophthalmology 113: 324-32, 2006
36. Trip SA, Schlottmann PG, Jones SJ, et al: Optic nerve atrophy and retinal nerve fibre layer thinning following optic neuritis: evidence that axonal loss is a substrate of MRI-detected atrophy. Neuroimage 31: 286-93, 2006
37. Beck RW, Cleary PA, Trobe JD, et al: The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. The Optic Neuritis Study Group. N Engl J Med 329: 1764-9, 1993
38. Arnold AC: Evolving management of optic neuritis and multiple sclerosis. Am J Ophthalmol 139: 1101-8, 2005
39. Beck RW, Gal RL, Bhatti MT, et al: Visual function more than 10 years after optic neuritis: experience of the optic neuritis treatment trial. Am J Ophthalmol 137: 77-83, 2004
40. Ruprecht K, Klinker E, Dintelmann T, et al: Plasma exchange for severe optic neuritis: treatment of 10 patients. Neurology 63: 1081-3, 2004
41. Roed HG, Langkilde A, Sellebjerg F, et al: A double-blind, randomized trial of IV immunoglobulin treatment in acute optic neuritis. Neurology 64: 804-10, 2005
42. Noseworthy JH, O'Brien PC, Petterson TM, et al: A randomized trial of intravenous immunoglobulin in inflammatory demyelinating optic neuritis. Neurology 56: 1514-22, 2001
43. Beck RW, Trobe JD, Moke PS, et al: High- and low-risk profiles for the development of multiple sclerosis within 10 years after optic neuritis: experience of the optic neuritis treatment trial. Arch Ophthalmol 121: 944-9, 2003
44. _: Long-term brain magnetic resonance imaging changes after optic neuritis in patients without clinically definite multiple sclerosis. Arch Neurol 61: 1538-41, 2004
45. Tintoré M, Rovira A, Rio J, et al: Is optic neuritis more benign than other first attacks in multiple sclerosis?. Ann Neurol 57: 210-5, 2005
46. Söderström M, Ya-Ping J, Hillert J, et al: Optic neuritis: prognosis for multiple sclerosis from MRI, CSF, and HLA findings. Neurology 50: 708-14, 1998
47. Nilsson P, Larsson EM, Maly Sundgren P, et al: Predicting the outcome of optic neuritis: evaluation ofrisk factors after 30 years of follow-up. J Neurol 252: 396-402, 2005
48. Lucchinetti CF, Kiers L, O'Duffy A, et al: Risk factors for developing multiple sclerosis after childhood optic neuritis. Neurology 49: 1413-8, 1997
49. Kappos L, Polman CH, Freedman MS, et al: Treatment with interferon beta-1 b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 67: 1242-9, 2006
50. Rudick RA: Impact of disease-modifying therapies on brain and spinal cord atrophy in multiple sclerosis. J Neuroimaging 14: 54S-64S, 2004
51. Comi G, Filippi M, Barkhof F, et al: Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancer 357: 1576-82, 2001
52. Jacobs LD, Beck RW, Simon JH, et al: Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 343: 898-904, 2000
53. Frohman EM, Havrdova E, Lublin F, et al: Most patients with multiple sclerosis or a clinically isolated demyelinating syndrome should be treated at the time of diagnosis. Arch Neurol 63: 614-9, 2006
54. Plant GT, Kermode AG, Turano G, et al: Symptomatic retrochiasmal lesions in multiple sclerosis: clinical features, visual evoked potentials, and magnetic resonance imaging. Neurology 42: 68-76, 1992
55. Borruat FX, Siatkowski RM, Schatz NJ, et al: Congruous quadrantanopia and optic radiation lesion. Neurology 43: 1430-2, 1993
56. Gündüz K, Cansu K, Bulduklar S, et al: Homonymous hemianopsia as the initial manifestation of multiple sclerosis. Ophthalmologica 212: 215-20, 1998
57. Fujimoto N, Adachi-Usami E: Use of blue-on-yellow perimetry to demonstrate quadrantanopia in multiple sclerosis. Arch Ophthalmol 116: 828-9, 1998
58. Frederiksen JL, Larsson HB, Nordenbo AM, et al: Plaques causing hemianopsia or quadrantanopsia in multiple sclerosis identified by MRI and VEP. Acta Ophthalmol (Copenh) 69: 169-77, 1991
59. Hornabrook RS, Miller DH, Newton MR, et al: Frequent involvement of the optic radiation in patients with acute isolated optic neuritis. Neurology 42: 77-9, 1992
60. Biousse V, Trichet C, Bloch-Michel E, et al: Multiple sclerosis associated with uveitis in two large clinic-based series. Neurology 52: 179-81, 1999
61. Zein G, Berta A, Foster CS: Multiple sclerosis-associated uveitis. Ocul Immunol Inflamm 12: 137-42, 2004
62. Towler HM, Lightman S: Symptomatic intraocular inflammation in multiple sclerosis. Clin Experiment Ophthalmol 28: 97-102, 2000
63. Prieto JF, Dios E, Gutierrez JM, et al: Pars planitis: epidemiology, treatment, and association with multiple sclerosis. Ocul Immunol Inflamm 9: 93-102, 2001
64. Arnold AC, Pepose JS, Hepler RS, et al: Retinal periphlebitis and retinitis in multiple sclerosis. I. Pathologic characteristics. Ophthalmology 91: 255-62, 1984
65. Engell T: Neurological disease activity in multiple sclerosis patients with periphlebitis retinae. Acta Neurol Scand 73: 168-72, 1986
66. Tola MR, Granieri E, Casetta I, et al: Retinal periphlebitis in multiple sclerosis: a marker of disease activity?. Eur Neurol 33: 93-6, 1993
67. Engell T, Andersen PK: The frequency of periphlebitis retinae in multiple sclerosis. Acta Neurol Scand 65: 601-8, 1982
68. Engell T, Jensen OA, Klinken L: Periphlebitis retinae in multiple sclerosis. A histopathological study of two cases. Acta Ophthalmol (Copenh) 63: 83-8, 1985
69. Hörnsten G: The relation of retinal periphlebitis to multiple sclerosis and other neurological disorders. Acta Neurol Scand 47: 413-25, 1971
70. Serra A, Derwenskus J, Downey DL, et al: Role of eye movement examination and subjective visual vertical in clinical evaluation of multiple sclerosis. J Neurol 250: 569-75, 2003
71. Thömke F, Lensch E, Ringel K, et al: Isolated cranial nerve palsies in multiple sclerosis. J Neurol Neurosurg Psychiatry 63: 682-5, 1997
72. Bentley PI, Kimber T, Schapka AH: Painful third nerve palsy in MS. Neurology 58: 1532, 2002
73. Frohman EM, Dewey RB, Frohman TC: An unusual variant of the dorsal midbrain syndrome in MS: clinical characteristics and pathophysiologic mechanisms. Mult Scler 10: 322-5, 2004
74. Lee WB, Berger JR, O'Halloran HS: Parinaud syndrome heralding MS. Neurology 60: 322, 2003
75. Milea D, Napolitano M, Dechy H, et al: Complete bilateral horizontal gaze paralysis disclosing multiple sclerosis. J Neurol Neurosurg Psychiatry 70: 252-5, 2001
76. Wall M, Wray SH: The one-and-a-half syndrome - a unilateral disorder of the pontine tegmentum: a study of 20 cases and review of the literature. Neurology 33: 971-80, 1983
77. de Seze J, Vukusic S, Viallet-Marcel M, et al: Unusual ocular motor findings in multiple sclerosis. J Neurol Sci 243: 91-5, 2006
78. Jacobson DM, Moster ML, Eggenberger ER, et al: Isolated trochlear nerve palsy in patients with multiple sclerosis. Neurology 53: 877-9, 1999
79. Sandramouli S, Benamer HT, Mantle M, et al: See-saw nystagmus as the presenting sign in multiple sclerosis. J Neuroophthalmol 25: 56-7, 2005
80. Matsumoto S, Ohyagi Y, Inoue I, et al: Periodic alternating nystagmus in a patient with MS. Neurology 56: 276-7, 2001
81. Shery T, Proudlock FA, Sarvananthan N, et al: The effects of gabapentin and memantine in acquired and congenital nystagmus: a retrospective study. Br J Ophthalmol 90: 839-43, 2006
82. Bandini F, Castello E, Mazzella L, et al: Gabapentin but not vigabatrin is effective in the treatment of acquired nystagmus in multiple sclerosis: How valid is the GABAergic hypothesis?. J Neurol Neurosurg Psychiatry 71: 107-10, 2001
83. Averbuch-Heller L, Tusa RJ, Fuhry L, et al: A double-blind controlled study of gabapentin and baclofen as treatment for acquired nystagmus. Ann Neurol 41: 818-25, 1997
84. Jain S, Proudlock F, Constantinescu CS, et al: Combined pharmacologic and surgical approach to acquired nystagmus due to multiple sclerosis. Am J Ophthalmol 134: 780-2, 2002